We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.41%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$121M
Cap. Flow
-$26.6M
Cap. Flow %
-1.23%
Top 10 Hldgs %
45.97%
Holding
84
New
9
Increased
5
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$53.6M
2
LEGN icon
Legend Biotech
LEGN
+$39.2M
3
AKRO
Akero Therapeutics
AKRO
+$38.7M
4
IMGN
Immunogen Inc
IMGN
+$35M
5
ARGX icon
argenx
ARGX
+$29.5M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$204M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$40.5M
3
BLU
BELLUS Health Inc.
BLU
+$23M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$7.53M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
51
DELISTED
Centessa Pharmaceuticals
CNTA
$7.75M 0.36%
1,251,137
– –
CABA icon
52
Cabaletta Bio
CABA
$437M
$6.97M 0.32%
540,000
– –
COGT icon
53
Cogent Biosciences
COGT
$6.65B
$6.22M 0.29%
525,000
– –
IRON icon
54
Disc Medicine
IRON
$2.94B
$5.77M 0.27%
130,000
– –
RAPT
55
DELISTED
RAPT Therapeutics
RAPT
$5.61M 0.26%
37,500
– –
TSVT
56
DELISTED
2seventy bio
TSVT
$4.65M 0.22%
459,836
– –
GOSS icon
57
Gossamer Bio
GOSS
$82.9M
$4M 0.19%
3,336,928
– –
RNAC icon
58
Cartesian Therapeutics
RNAC
$229M
$3.68M 0.17%
109,469
– –
MRSN
59
DELISTED
Mersana Therapeutics
MRSN
$3.29M 0.15%
+40,000
New +$5.85M
THRX
60
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$3.27M 0.15%
350,000
– –
MREO
61
Mereo BioPharma
MREO
$54.7M
$2.97M 0.14%
2,250,000
– –
DBVT
62
DBV Technologies
DBVT
$799M
$2.75M 0.13%
145,000
– –
THRD
63
DELISTED
Third Harmonic Bio
THRD
$2.74M 0.13%
570,417
– –
FATE icon
64
Fate Therapeutics
FATE
$286M
$2.38M 0.11%
500,000
– –
BCEL
65
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.16M 0.1%
2,202,333
– –
BCAB icon
66
BioAtla
BCAB
$5.46M
$2.06M 0.1%
13,727
– –
MIST icon
67
Milestone Pharmaceuticals
MIST
$138M
$1.99M 0.09%
698,861
– –
EQRX
68
DELISTED
EQRx, Inc. Common Stock
EQRX
$1.86M 0.09%
1,000,000
– –
OBIO icon
69
Orchestra BioMed
OBIO
$238M
$1.75M 0.08%
250,000
– –
KNTE
70
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.49M 0.07%
491,000
-19,000
-4% -$73.2K
RAIN
71
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$1.38M 0.06%
1,152,212
-995,000
-46% -$4.98M
NGM
72
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.29M 0.06%
500,000
– –
LITS
73
Lite Strategy Inc
LITS
$32.8M
$958K 0.04%
145,654
-1
-0% -$6
TCRT icon
74
Alaunos Therapeutics
TCRT
$4.59M
$765K 0.04%
10,000
– –
TARA icon
75
Protara Therapeutics
TARA
$220M
$500K 0.02%
209,227
– –
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Boxer Capital held 84 positions worth $2.16B, up 5.9% from $2.04B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital's Q2 2023 filing shows 9 new, 5 increased, 5 reduced and 5 closed positions. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M. The largest sale was Prometheus Biosciences, Inc. Common Stock, an estimated $204M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2023 buy was Karuna Therapeutics, Inc. Common Stock: 250,000 shares worth $54.2M.
  • Boxer Capital added most to Akero Therapeutics in Q2 2023, an estimated $38.7M increase.
  • Boxer Capital's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $22.6M.
  • Boxer Capital fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $204M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.16B portfolio in Q2 2023.
  • Boxer Capital opened 9 new positions and closed 5 in Q2 2023.
  • Boxer Capital's portfolio value rose 5.9% quarter-over-quarter to $2.16B.

Based on Boxer Capital's 13F filing for Q2 2023, filed 14 Aug 2023.